Stock Analiz

AEON Biopharma, Inc. AEON

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.15Market cap $11M
Open the interactive analysis →

AEON Biopharma, Inc. (AEON) is a healthcare company listed in the US with a market value of about $11M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).

About AEON Biopharma

AEON Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 2 of the last 4 years in our data.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-158.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)—
Profitable years (of last 10)2
Years paying a dividend—

Financials, last 4 years

Fiscal year2025202420222021
Revenue————
Net income-$39M$42M-$53M$8M
Free cash flow-$17M—-$36M—
EPS (diluted)$-3.95$72.93$-0.38—
Net margin————
ROIC————

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does AEON Biopharma pay a dividend?

Not currently.

Is AEON Biopharma a good stock to buy?

We do not give buy or sell advice. AEON Biopharma scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.